# Mirvetuximab Soravtansine as First Line in Treating Patients With Triple Negative Breast Cancer

> **NCT03106077** · PHASE2 · COMPLETED · sponsor: **M.D. Anderson Cancer Center** · enrollment: 96 (actual)

## Conditions studied

- Anatomic Stage II Breast Cancer AJCC v8
- Anatomic Stage IIA Breast Cancer AJCC v8
- Anatomic Stage IIB Breast Cancer AJCC v8
- Anatomic Stage III Breast Cancer AJCC v8
- Anatomic Stage IIIA Breast Cancer AJCC v8
- Anatomic Stage IIIB Breast Cancer AJCC v8
- Anatomic Stage IIIC Breast Cancer AJCC v8
- Anatomic Stage IV Breast Cancer AJCC v8
- Estrogen Receptor Negative
- Folate Receptor Alpha Positive
- HER2/Neu Negative
- Progesterone Receptor Negative
- Prognostic Stage II Breast Cancer AJCC v8
- Prognostic Stage IIA Breast Cancer AJCC v8
- Prognostic Stage IIB Breast Cancer AJCC v8
- Prognostic Stage III Breast Cancer AJCC v8
- Prognostic Stage IIIA Breast Cancer AJCC v8
- Prognostic Stage IIIB Breast Cancer AJCC v8
- Prognostic Stage IIIC Breast Cancer AJCC v8
- Prognostic Stage IV Breast Cancer AJCC v8
- Triple-Negative Breast Carcinoma

## Interventions

- **BIOLOGICAL:** Mirvetuximab Soravtansine

## Key facts

- **NCT ID:** NCT03106077
- **Lead sponsor:** M.D. Anderson Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-06-05
- **Primary completion:** 2019-10-01
- **Final completion:** 2019-10-01
- **Target enrollment:** 96 (ACTUAL)
- **Last updated:** 2020-12-02

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03106077

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03106077, "Mirvetuximab Soravtansine as First Line in Treating Patients With Triple Negative Breast Cancer". Retrieved via AI Analytics 2026-05-29 from https://api.ai-analytics.org/clinical/NCT03106077. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*